Publications by authors named "A N Billin"
Article Synopsis
- - Clinical trials for metabolic dysfunction-associated steatohepatitis (MASH) need accurate histologic scoring to assess participants and outcomes, but varying interpretations have affected results.
- - The AI-based tool AIM-MASH showed strong consistency and agreement with expert pathologists in scoring MASH histology, achieving accuracy comparable to that of average pathologists.
- - AIM-MASH demonstrated a strong ability to predict patient outcomes, correlating well with pathologist scores and noninvasive biomarkers, indicating it could enhance the efficiency and reliability of clinical trials for MASH.
Article Synopsis
- This phase 1b study assessed the safety and effectiveness of cilofexor, a drug targeting farnesoid X receptors, in patients with compensated cirrhosis caused by primary sclerosing cholangitis over 12 weeks.
- Patients received increasing doses of cilofexor, and while most reported side effects like pruritus and fatigue, there were no serious adverse events.
- Results showed significant improvements in liver function markers, indicating that cilofexor may help manage cholestasis in these patients.
Background: Family caregivers of people with high-grade glioma often report high rates of psychological distress, which has been attributed to the unique aspects of the disease and onerous care demands. Clinical practice guidelines advocate for caregiver support from diagnosis through to end-of-life and bereavement. Yet, research has identified that caregivers' support needs are often overlooked.
View Article and Find Full Text PDFThe Wilderness Medical Society convened a panel to review available evidence supporting practices for medical direction of search and rescue teams. This panel included of members of the Wilderness Medical Society Search and Rescue Committee, the National Association of EMS Physicians Wilderness Committee, and leadership of the Mountain Rescue Association. Literature about definitions and terminology, epidemiology, currently accepted best practices, and regulatory and legal considerations was reviewed.
View Article and Find Full Text PDFArticle Synopsis
- Clinical trials for nonalcoholic steatohepatitis (NASH) rely on consistent histologic scoring, but variability in these interpretations has affected trial results.* -
- An AI tool called AIM-NASH was developed to provide standardized scoring for NASH histology, showing strong correlation with expert consensus scores and improving predictive accuracy for patient outcomes.* -
- In a retrospective analysis, AIM-NASH helped meet previously unmet pathological endpoints in the ATLAS trial, suggesting it could reduce variability in scoring and enhance the assessment of treatment responses in clinical trials.*